Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $94.20 Consensus Target Price from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) has been given an average rating of "Moderate Buy" by the five ratings firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $94.20.

PBH has been the subject of a number of analyst reports. DA Davidson upped their price target on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a "buy" rating in a research report on Wednesday, August 28th. Jefferies Financial Group restated a "hold" rating and issued a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th.

Prestige Consumer Healthcare Price Performance

PBH traded up $2.95 on Thursday, hitting $80.59. 124,742 shares of the company's stock were exchanged, compared to its average volume of 246,502. Prestige Consumer Healthcare has a fifty-two week low of $56.61 and a fifty-two week high of $81.25. The stock has a market cap of $3.99 billion, a price-to-earnings ratio of 18.93, a P/E/G ratio of 2.08 and a beta of 0.47. The firm has a 50-day moving average price of $72.31 and a 200-day moving average price of $69.71. The company has a current ratio of 3.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.65.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, topping analysts' consensus estimates of $0.86 by $0.04. The firm had revenue of $267.10 million for the quarter, compared to analyst estimates of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. Prestige Consumer Healthcare's quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.06 earnings per share. As a group, equities analysts anticipate that Prestige Consumer Healthcare will post 4.43 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Opal Wealth Advisors LLC purchased a new stake in Prestige Consumer Healthcare in the 2nd quarter valued at about $26,000. Quest Partners LLC lifted its holdings in shares of Prestige Consumer Healthcare by 2,826.7% in the 2nd quarter. Quest Partners LLC now owns 439 shares of the company's stock worth $30,000 after acquiring an additional 424 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Prestige Consumer Healthcare by 80.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company's stock worth $33,000 after acquiring an additional 208 shares during the last quarter. Gladius Capital Management LP purchased a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth approximately $35,000. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock valued at $35,000 after purchasing an additional 433 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.